

Seventh EGF repeat 11% /NA  
Eighth EGF repeat 44%  
Ninth EGF repeat 29% /NA  
Cysteine knot motif 34%

NA: not applicable due to absence of homologous repeat.

Figures for individual LLRs are shown in brackets.--

Immediately prior to the claims, please insert the enclosed 23 page section entitled "SEQUENCE LISTING".

Please delete all pages after page 17.

#### REMARKS

These amendments are intended to address Sequence Listing formalities and to incorporate the sections appended to the application as filed in the following manner:

(1) by relocating the bodies and headings of Tables 3 and 4 (appended to the specification as filed) to page 6, renumbering them Tables 1 and 2 respectively and reformatting the shaded areas as open boxes.

(2) by renumbering Tables 1 and 2 as filed, as Tables 3 and 4 respectively.


(3) by relocating Tables 5 (A-B) and 6 (appended to the specification as filed) and the text accompanying these tables to page 11, and renumbering Table 5 (A-B) as Table 5.

(4) by relocating the sections entitled "Features of Human Slit Predicted Protein" and "Amino acid identity between Drosophila and Human Slit-1" (appended to the specification as filed) to follow Table 6.

(5) by relocating the data of "SEQ ID NO:1 & 2" (appended to the specification as filed) to a section entitled "SEQUENCE LISTING" immediately prior to the claims. The sequences disclosed in this sequence listing are identical to those disclosed in the deleted "SEQ ID NO:1 & 2" and Tables 3 and 4, as originally filed.

The foregoing amendments introduce no new matter.

Respectfully submitted,  
SCIENCE & TECHNOLOGY LAW GROUP

  
Richard Aron Osman, Ph.D., Reg. No. 36,627  
Tel: (650) 343-4341